Anthem Biosciences Limited has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Tuesday, May 19, 2026. The intimation has been filed pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The Board meeting has been convened to address key financial and corporate matters for the fiscal year. The following items are on the agenda:

The company's Bengaluru-based Board will deliberate on the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, alongside a possible recommendation of a final dividend for the same period.

Trading Window Closure

In line with regulatory requirements, Anthem Biosciences has enforced a trading window restriction for all insiders. As per the company's previous communication dated March 27, 2026, the trading window for dealing in the company's equity shares has been closed from April 01, 2026 and will remain shut until the close of trading hours on May 21, 2026—48 hours after the declaration of the financial results.

This measure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's own Code of Conduct governing the regulation, monitoring, and reporting of trading by employees and other connected persons.

Regulatory Compliance

The intimation has been duly signed by Divya Prasad, Company Secretary and Compliance Officer (Membership No: A41438), on May 12, 2026. The company has also made this disclosure available on its investor relations webpage at https://anthembio.com/investors/ . Anthem Biosciences, formerly known as Anthem Biosciences Private Limited, is headquartered at Bommasandra Industrial Area, Phase - I, Bengaluru - 560 099, Karnataka, India.

Anthem Biosciences Limited's Board of Directors convened on April 22, 2026, from 2:30 PM to 3:32 PM IST, approving two significant corporate matters requiring regulatory disclosure under SEBI guidelines. The company formally notified BSE and NSE about the appointment of new statutory auditors and approval of an upside sharing arrangement involving substantial financial implications.

Statutory Auditor Transition

The Board approved the appointment of new statutory auditors following the Audit Committee's recommendation. The current auditors, K.P. Rao & Co., Chartered Accountants, will complete their tenure at the conclusion of the twentieth Annual General Meeting scheduled for financial year 2026-2027.

The incoming audit firm, established in 1949 with its registered office in Kolkata, operates across key Indian cities and maintains a network of affiliated firms providing audit and assurance services to diverse market segments including Industrial, Infrastructure, Consumer Products, Financial Services, Technology, Media and Entertainment, Telecommunications and Professional Services.

Upside Sharing Arrangement Approval

The Board approved an existing upside sharing arrangement under Regulation 26(6) of SEBI LODR, recommending it for public shareholder approval through an ordinary resolution. This arrangement stems from the Shareholders' Agreement dated March 01, 2021, as amended by the Waiver-cum-Amendment Agreement dated December 30, 2024.

The arrangement involves sharing returns from Viridity Tone LLP's post-listing equity share divestment when the investor's returns exceed specific thresholds. The upside sharing mechanism activates when returns surpass the higher of 25% of the invested amount or 2 times the original investment.

Recent Transaction Impact

The upside sharing arrangement became operational following Viridity Tone LLP's significant divestment on March 09, 2026. The transaction involved the sale of equity shares, generating substantial proceeds and triggering the upside sharing mechanism.

Regulatory Compliance and Documentation

Both matters align with SEBI's listing obligations and disclosure requirements. The company has ensured comprehensive documentation with the Shareholders' Agreement and Waiver-cum-Amendment Agreement available on the company's investor website. The salient terms were previously disclosed in the July 16, 2025 prospectus under "History and Certain Corporate Matters."

Appropriate disclosures regarding the upside sharing arrangement will be included in the notice for the twentieth Annual General Meeting. The company secretary Divya Prasad signed the regulatory filing, confirming compliance with all applicable regulations and maintaining transparency with stakeholders and regulatory authorities.